Ozempic does not increase leptin levels
Furthermore, dual-action compounds engaging GLP-1 combined with glucose-dependent insulinotropic polypeptide (GIP) or glucagon pathways, alongside triple agonists incorporating all three receptors activation, have exhibited enhanced therapeutic potential
In the UK, Wegovy is licensed for adults with a BMI of 30 kg/m or greater (obesity), or from 27 kg/m to less than 30 kg/m (overweight) in the presence of at least one weight-related comorbidity
Crnkovic S, Egemnazarov B, Jain P, Seay U, Gattinger N, Marsh LM, Balint Z, Kovacs G, Ghanim B, Klepetko W, et al
doi: [Research Gate] Cascalheira JF, Parreira MC, Viegas AN, Faria MC, Domingues FC
The trade-off is potency